Core Insights - The article discusses the recent implementation of the commercial health insurance innovative drug directory and the challenges it faces in terms of hospital procurement, prescription issuance, and payment processes [1][15] - The "three exclusions" policy is highlighted as a crucial factor for facilitating the entry of innovative drugs into hospitals, which includes exemptions from basic medical insurance self-payment rates, collection of alternative products, and payment by disease category [2][18] Group 1: Implementation of the Commercial Health Insurance Directory - As of December 8, following the national medical insurance negotiations, at least 20 provinces have issued notifications for the online procurement of the commercial health insurance innovative drug directory [2][15] - The directory includes 19 high-value innovative drugs, but the industry is concerned about how these drugs will navigate the challenges of hospital entry, prescription issuance, and payment [2][15] Group 2: The "Three Exclusions" Policy - The "three exclusions" policy is seen as a key to overcoming the barriers to drug entry and prescription issuance, allowing commercial insurance directory drugs to bypass certain cost control measures of basic medical insurance [2][18] - However, there are currently no clear guidelines for the implementation of the "three exclusions" policy, leading to skepticism among hospital pharmacists regarding their interest in procuring these drugs without incentives [2][16] Group 3: Challenges in Hospital Procurement - The DRG (Diagnosis-Related Group) exclusion is identified as the most complex aspect of the "three exclusions" policy, which is essential for allowing hospitals to procure commercial health insurance directory drugs without financial loss [3][19] - Hospitals face significant pressure regarding drug management costs, and without proper incentives, their interest in purchasing these innovative drugs remains limited [2][16] Group 4: Comparison with National Negotiated Drugs - Despite the introduction of favorable policies for national negotiated drugs, they still face slow integration into hospitals, with only a limited number of these drugs being routinely stocked in hospitals [8][22] - The article suggests that the experience of Shanghai's "new and excellent drug and device" list could provide insights for improving the entry of commercial health insurance directory drugs into hospitals [9][23] Group 5: Alternative Distribution Channels - There is a suggestion that pharmacies could serve as an alternative distribution channel for the commercial health insurance directory drugs, similar to previous attempts with national negotiated drugs [12][25] - The success of this approach would depend on balancing patient access to medications with the insurance companies' risk management strategies [12][26] Group 6: Market Growth and Policy Synergy - The growth of the commercial health insurance market is crucial for the successful implementation of the directory, as it requires a sufficient market demand to support hospital procurement and prescription issuance [13][26] - The interaction between the "three exclusions" policy and the commercial health insurance market will be key to fostering a positive cycle that promotes the development of innovative drugs [13][26]